<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="HBV–DNA. Twenty (37,0%) received lamivudine + adefovir, 20 (37.0%) tenofovir, 2 (3.7%)" exact="lamivudine" post="and 12 (22.2%) entecavir. Therapy median duration was 38"/>
 <result pre="compared to Group C (p = 0.00003 and p = 0.00006, respectively). Tenofovir and" exact="entecavir" post="showed less impact compared to lamivudine + adefovir. mtDNA/nDNA ratio positively"/>
 <result pre="showing significant differences in mtDNA and mtRNA levels. Tenofovir and" exact="entecavir" post="showed lower impact on alterations, compared to 1st generation"/>
 <result pre="HBeAg-antibody serological expression2. First generation Nucleos(t)ide Analogues (NAs), such as" exact="lamivudine" post="and adefovir, showed a high antiviral efficacy, but their"/>
 <result pre="HBV-DNA and with HBsAg loss, first generation NAs such as" exact="lamivudine" post="are still used for HBV reactivation prophylaxis6. A long-term"/>
 <result pre="20 (37,0%) were receiving lamivudine + adefovir, 20 (37,0%) tenofovir, 2 (3,7%)" exact="lamivudine" post="monotherapy and 12 (22,2%) entecavir monotherapy. Among NAs treated"/>
 <result pre="20 (37,0%) tenofovir, 2 (3,7%) lamivudine monotherapy and 12 (22,2%)" exact="entecavir" post="monotherapy. Among NAs treated patients, only 1/54 (4.5%) had"/>
 <result pre="currently receiving entecavir, 73 months (IQR 57–108) in those receiving" exact="tenofovir" post="and 96 months (IQR 66–150) in those treated with"/>
 <result pre="only statistically significant difference in total therapy duration was between" exact="entecavir" post="and tenofovir treated patients (p = 0.001) whereas, even if the"/>
 <result pre="significant difference in total therapy duration was between entecavir and" exact="tenofovir" post="treated patients (p = 0.001) whereas, even if the median total"/>
 <result pre="longer, only a trend toward significance was observed when comparing" exact="entecavir" post="and lamivudine + adefovir (p = 0.087). Among patients receiving tenofovir, 12/20 (60%)"/>
 <result pre="2/20 (10%) with lamivudine + entecavir and 3/10 (15%) have received only" exact="tenofovir" post="monotherapy. Among patients treated with entecavir, 5/12 (41.7%) have"/>
 <result pre="and APRI score values when considering separately patients currently receiving" exact="entecavir" post="monotherapy, tenofovir monotherapy and lamivudine + adefovir. Table 1 Demographic, clinical"/>
 <result pre="score values when considering separately patients currently receiving entecavir monotherapy," exact="tenofovir" post="monotherapy and lamivudine + adefovir. Table 1 Demographic, clinical and therapeutic"/>
 <result pre="and uninfected controls (Group C). ETV: entecavir, LAM + ADV: lamivudine + adefovir, TDF:" exact="tenofovir" post="disoproxil fumarate; data are showed as: median (point), box"/>
 <result pre="to single drug regimen after excluding the 2 patients receiving" exact="lamivudine" post="monotherapy. mtDNA/nDNA ratio levels were significantly higher in patients"/>
 <result pre="on therapy with lamivudine + adefovir (Fig. 2) compared to those receiving" exact="entecavir" post="(p = 0.025), to Group B (p = 0.00006) and Group C (p = 0.00003)."/>
 <result pre="to Group B (p = 0.00006) and Group C (p = 0.00003). Patients receiving" exact="tenofovir" post="had significantly higher mtDNA/nDNA ratio levels when compared to"/>
 <result pre="compared to patients receiving entecavir, tough not significantly. Patients receiving" exact="entecavir" post="had significantly higher levels when compared to Group C"/>
 <result pre="significantly lower mtRNA/nRNA ratio values when compared to patients receiving" exact="tenofovir" post="(p = 0.027) and entecavir (p = 0.011). Patients receiving lamivudine + adefovir had also"/>
 <result pre="ratio values when compared to patients receiving tenofovir (p = 0.027) and" exact="entecavir" post="(p = 0.011). Patients receiving lamivudine + adefovir had also significantly lower mtRNA/nRNA"/>
 <result pre="(p = 0.0039) and Group C (p = 0.0000001). Furthermore, no statistical difference between" exact="entecavir" post="and tenofovir recipients was observed (Fig. 2). mtDNA/nDNA ratio"/>
 <result pre="Group C (p = 0.0000001). Furthermore, no statistical difference between entecavir and" exact="tenofovir" post="recipients was observed (Fig. 2). mtDNA/nDNA ratio levels significantly"/>
 <result pre="treatment with lamivudine + adefovir, never changed this schedule. Instead, patients receiving" exact="tenofovir" post="or entecavir, were previously exposed to lamivudine + adefovir in 16/20"/>
 <result pre="patients receiving lamivudine + adefovir, in 3/19 (15.7%) among patients treated with" exact="tenofovir" post="and in 0/11(0%) of patients receiving entecavir. It is"/>
 <result pre="It is noteworthy that 2/3 patients with BSC currently receiving" exact="tenofovir" post="had previously been exposed to lamivudine + adefovir. When comparing the"/>
 <result pre="in CK levels was observed in 12.9% of patients receiving" exact="telbivudine" post="and in 4.1% patients of those receiving lamivudine for"/>
 <result pre="patients receiving telbivudine and in 4.1% patients of those receiving" exact="lamivudine" post="for 104 weeks (p &amp;lt; 0.001). Myopathy, has also been reported"/>
 <result pre="3 patients, all of whom had resolution of symptoms after" exact="telbivudine" post="was discontinued29. Regarding 2nd generation NAs, entecavir has been"/>
 <result pre="of symptoms after telbivudine was discontinued29. Regarding 2nd generation NAs," exact="entecavir" post="has been rarely associated with clinical signs of mitochondrial"/>
 <result pre="failed to detect an increased risk of lactic acidosis in" exact="entecavir" post="recipients30. Furthermore, to our knowledge, tenofovir has never been"/>
 <result pre="of lactic acidosis in entecavir recipients30. Furthermore, to our knowledge," exact="tenofovir" post="has never been associated with lactic acidosis in HBV-infected"/>
 <result pre="lymphoma treated with a combination of adefovir/lamivudine, when compared to" exact="lamivudine" post="alone33. Therefore, the use of 1st generation NAs also"/>
 <result pre="lamivudine + adefovir had higher levels of mtDNA, compared to those receiving" exact="entecavir" post="or tenofovir, suggesting that the impact on mitochondrial damage"/>
 <result pre="in mtDNA levels in children exposed to zidovudine/lamivudine compared to" exact="zidovudine" post="alone. This study also suggests that exposure to combination"/>
 <result pre="but no change in mtDNA levels after 4 weeks of" exact="zidovudine" post="treatment in mouse muscle cells43. In our study, the"/>
 <result pre="not appear to be critical. Among drugs, 2nd generation NA" exact="tenofovir" post="and entecavir showed a lower impact on mitochondrial alterations"/>
 <result pre="to be critical. Among drugs, 2nd generation NA tenofovir and" exact="entecavir" post="showed a lower impact on mitochondrial alterations compared to"/>
 <result pre="DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of" exact="stavudine" post="containing antiretroviral therapy in HIV-infected Malawian patientsOMICS.20141843844510.1089/omi.2014.002624816082 11.MontanerJSet al.Mitochondrial"/>
 <result pre="Syndr.200334Suppl 1S859010.1097/00126334-200309011-0001314562863 12.VidalFet al.In vitro cytotoxicity and mitochondrial toxicity of" exact="tenofovir" post="alone and in combination with other antiretrovirals in human"/>
 <result pre="16.VernochetCet al.Differential effect of HIV protease inhibitors on adipogenesis: intracellular" exact="ritonavir" post="is not sufficient to inhibit differentiationAIDS.2003172177218010.1097/00002030-200310170-0000514523274 17.SmithDEet al.Thymidine analogue"/>
 <result pre="the selectivity of the mitochondrial DNA polymeraseBiochemistry.200342147111471910.1021/bi035596s14674745 19.Pérez-MolinaJADomingoPMartínezEMorenoSThe role of" exact="efavirenz" post="compared with protease inhibitors in the body fat changes"/>
 <result pre="cellular perspectiveNat. Rev. Drug. Discov.2003281282210.1038/nrd120114526384 29.LiawYFet al.2-Year GLOBE trial results:" exact="telbivudine" post="is superior to lamivudine in patients with chronic hepatitis"/>
 <result pre="Discov.2003281282210.1038/nrd120114526384 29.LiawYFet al.2-Year GLOBE trial results: telbivudine is superior to" exact="lamivudine" post="in patients with chronic hepatitis BGastroenterology.200913648649510.1053/j.gastro.2008.10.02619027013 30.LamperticoPet al.Review article:"/>
</results>
